BTG CASE STUDIES > LIFE SCIENCE

Reorganizing the Global Pharmacovigilance Function

An F200 pharma company was reevaluating the operating model of its global drug safety and pharmacovigilance functions. Looking for help assessing cost, quality, and productivity impact of different resourcing scenarios, the group’s head turned to BTG. We delivered an independent pharmacovigilance organization specialist and former…

READ MORE


Pharmaceutical Target Valuation

The head of M&A at a global pharma company was evaluating an acquisition target based in India. His team had already assessed the company’s core business, but it needed help understanding the valuation of non-core assets in Europe and the U.S. Business Talent Group put…

READ MORE


Oncology Commercial Assessment

The head of commercial development at a global biopharma giant was assessing the outlook for several oncology indications in key Asian markets. The team had already secured secondary research sources, and it had contracted with external agencies to conduct primary research. However, there was no…

READ MORE


Reinventing Consulting

Leaders at this biopharma giant didn’t set out to reinvent the way the company sourced industry experts and management consultants. But after eight years and more than 150 successful projects in functions as diverse as strategy, market access, product launch, lifecycle management, and digital health—across…

READ MORE


Redesigning the Regulatory Submissions Process

The internal consulting group at a Fortune 200 pharmaceutical company was redesigning the organization’s regulatory submission process—and creating an integrated framework to use for planning all submissions. The group had already installed a technology solution to facilitate communication between the company’s headquarters and its individual…

READ MORE


Market Access Sales Training and Support

The pharmaceutical reimbursement landscape has grown increasingly complex and—thanks to an intensifying focus on improving clinical outcomes—increasingly competitive. Reimbursement was once a formality that followed regulatory approval. Now, it’s forcing life science companies to rethink their market access strategies and reorganize the way they develop…

READ MORE